Related Experiment Video
Updated: Aug 4, 2026

Isolation of Human Islets from Partially Pancreatectomized Patients
Published on: July 30, 2011
Noninsulinoma pancreatogenous hypoglycemia syndrome: an update in 10 surgically treated patients
G B Thompson1, F J Service, J C Andrews
1Division of Gastroenterologic and General Surgery, Mayo Clinic and Foundation, Rochester, MN 55905, USA.
Background:
Neuroglycopenia from endogenous hyperinsulinism usually is caused by insulinomas in adults. We recently reported a novel hypoglycemic disorder in 5 patients (patients 1 to 5) with postprandial neuroglycopenia, negative 72-hour fasts, negative perioperative imaging studies, but positive calcium stimulation tests and islet hypertrophy and nesidioblastosis in the gradient-guided resected pancreata.
Methods:
In this report we compare our experience with 5 additional patients (patients 6 to 10) with this syndrome to that in the original report.
Results:
The clinical features of patients 6 to 10 were similar to those of patients 1 to 5. Each had positive calcium stimulation testing that guided the extent of the distal pancreatectomy and histologic evidence of islet cell hypertrophy or nesidioblastosis. All 10 patients are alive from 9 to 50 months after operation, 1 of whom had no amelioration of neuroglycopenia. Minor perioperative complications occurred in 3 patients. One patient has experienced repeated bouts of acute pancreatitis, pseudocyst formation, and exocrine insufficiency.
Conclusions:
We have identified adult patients with severe, postprandial hyperinsulinemic hypoglycemia from diffuse islet cell disease, 80% of whom have been well palliated with surgery. The results in 7 men have been better than those in the 3 women for reasons that are not obvious.
Related Concept Videos
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Oral Hypoglycemic Agents: Glinides
Hypoglycemia and Glucagon
Type I Diabetes I: Introduction
Type I Diabetes III: Clinical Manifestations
Hypoglycemia

